



Optiscan Imaging Ltd (ASX:OIL)

Building A Global Medical Imaging And
Diagnostics Company

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 26 November 2020.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Notice

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Building A Global Scale Medical Imaging And Diagnostics Company

Board

Darren Lurie – CEO and Executive Chair

B.LLB (Hons) and B.COM (Hons)

Executive Chair since May 2018. Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia). Darren is a former chair and non-executive director of ASX listed Farm Pride Foods Ltd (ASX:FRM).

Dr Philip Currie – Non Executive Director

MBBS (Hons), FRACP, MBA

Dr Currie is a leading cardiologist with more than 35 years experience in medical research, clinical cardiology and business. He completed his cardiology fellowship at the prestigious Mayo Clinic, staff cardiologist at both Mayo Clinic and Cleveland Clinic and was the Director of Echocardiography at Michigan Heart and Vascular Institute.

Graeme Mutton – Non Executive Director

CPA

Graeme is a long-standing shareholder in Optiscan and has a deep understanding of Optiscan's technology and applications. He is a former manager of an accounting practice and successful business owner and operator.

Total Securities on Issue


- 596,730,300 Ordinary Shares
- 25,600,000 unlisted options

Market Capitalisation: ~A\$60million @10c

Capital Raising: \$9.8m @8.25c in September 2020




Milestones and Share Price Movement for 2020



Operating Cash Flow Summary

Net Cash Used In Operating Activities



Financial Years July to June (FY)

Calendar Year January to December (CY)

* Audited Results for January to June 2020 and unaudited results for July to October 2020

Optiscan's InVivage® Clinical Device

- ❑ Real-time “virtual biopsy” with instantaneous, sub-cellular resolution imaging
- ❑ Cancer Screening and Surgical Applications
- ❑ Button controls on probe enabling single handed operation
- ❑ Lodged patent application for new InVivage® features

Clinical Applications:


Oral Cancer



Breast Cancer



Cervical Cancer



Key Steps Towards FDA 510(k) for Optiscan's InVivage®

- US FDA Q-submission meeting in January 2020.
- Positive written and verbal feedback received from the FDA in October 2020 regarding the proposed 510(k) submission.
- Commencement of third-party testing required for the FDA 510(k) submission.
- Government funding secured for the Melbourne Dental School Oral cancer screening study.
- Intended 510(k) submission to be lodged in the first half of 2021.
- September Capital Raising provides the funding resources to pursue this and other regulatory approvals and clinical studies in additional markets and cancer applications.

OPTISCAN – Clinical Studies




Oral Cancer

- 150 patient Oral Cancer Study at Melbourne Dental School funded by Australian Government BioMedtech Horizons Program
- Oral Cancer Study at the Memorial Sloan Kettering Cancer Centre in New York.
- Oral Cancer Screening Study at the Australian Centre for Oral Oncology Research and Education in Perth.



Breast Cancer

- Ex vivo lumpectomy and mastectomy study at Western Australia's largest private hospital.
- Submitted ethics committee application for Royal Melbourne Hospital Breast Cancer Intraoperative Assessment Trial (ex vivo study).



Cervical & Oesophageal Cancer

- Ex vivo studies at Memorial Sloan Kettering Cancer Centre with planning for in vivo studies to commence.

Publications in 2020



Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for 'leaky-gut' in inflammatory bowel disease




Fluorescence-guided resection of tumors in mouse models of oral cancer



Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers



Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures



Building Government and Association Relationships

❑ Developing Government (State and Federal) and Biotechnology Industry connections:

- Global Victoria
- Invest Vic
- Department of Jobs (VIC)
- AusTrade
- Department of Industry
Science and Technology (Federal)
- Department of Health (Federal)
- MTP Connect
- CSIRO
- AusBiotech
- BioMelbourne Network

❑ Government Sponsored Invitations to Industry and Investment Conferences:

- Zhejiang International Technology Business Matching Webinar (estimated 60,000 online viewers)
- Austrade, AstraZeneca, Wuxi iCampus and CSIRO Virtual Conference
- China Smart HealthCare Conference – in conjunction with Melbourne Dental School

World Lip & Oral Cavity Cancer Incidence And Mortality

2%

Of all cancer
Incidence ¹

350k

New cases
in 2018 ¹

177k

Total deaths
in 2018 ¹

>80%
Survival

Early Diagnosis ²

57%
Survival

Late Diagnosis ²

2.5x
Cost

Early Vs Late ²

1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018. 68(6): p. 394-424.

2. Pollaers, K., et al., The economic burden of oral squamous cell carcinoma in Australia. Journal of Oral Pathology & Medicine, 2019. 48(7): p. 588-594. doi: 10.1111/jop.12907. Epub 2019 Jun 27.

Oral Cancer Market Size


United States

71 NCI Designated Cancer Centers ¹

900 Specialist Cancer Centers

6,146 Total US Hospitals

9,000 Oral and Maxillofacial Surgeons




Locations of National Cancer Institute (NCI) Designated Cancer Centers

China

786 Specialist Stomatological Hospitals in 2018 ²

Number and Growth of Stomatological (Dental) Specialist Hospitals in China from 2011 to 2018



■ Number of Stomatological Specialist Hospitals

1. <https://www.cancer.gov/research/infrastructure/cancer-centers/find>
2. Data courtesy of Australian Trade and Investment Commission (AusTrade)

Breast Cancer - Most Common Cancer in Women

**2.1
Million**

2.1 million new cases of breast cancer predicted in 2018 (globally) ¹

15%

15% of all new cancer cases in the US are breast cancer ²

8.5%

8.5% of all new cancer cases in China are breast cancer ³

- 20-30% of lumpectomy patients currently require repeat surgery with current practice (histopathology analysis) often taking up to 3-4 days post initial surgery.
- Detection and treatment of positive tumour margin at the time of surgery will reduce the requirement for repeat surgeries with reduced emotional trauma, physical pain and costs for patient and hospital

1. Bray et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68: 394-424. doi:[10.3322/caac.21492](https://doi.org/10.3322/caac.21492)

2. American Cancer Society Estimated 2019 statistics

3. Feng et al. (2019). Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer communications (London, England), 39(1), 22. <https://doi.org/10.1186/s40880-019-0368-6>

CONVIVO® – Carl Zeiss Meditec (CZM) Co-operation

- ❑ FDA 510(k) clearance, CE Mark and TGA approval obtained
- ❑ Final Milestone payment received and movement to production phase
- ❑ Trials using CONVIVO in brain tumor resection are underway in Europe and United States and proposed in Australia for 2021
- ❑ “this probably is the most exciting technology that I have seen in my career come through the laboratory.”
- Mark C Preul, Neurosurgeon, Barrow Neurosurgical Institute, Arizona, United States.



297K
Brain and CNS
cancer cases
every year
worldwide¹

1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018. 68(6): p. 394-424.

Distribution Model for the Preclinical Device (FIVE2)

China



- ❑ South and West China Distributor:
Guangzhou Yunxing

- ❑ East China Distributor:
Biotimes Technology Limited

- ❑ **3 Sales since late 2019**

- ❑ Initiated discussions with potential Taiwanese distributor

Asia Pacific




- ❑ Appointment of Asia Pacific Distribution Manager

- ❑ Replication of China marketing strategy with experienced applications scientist Dr Joseph Jiafu

- ❑ Initiated discussions with potential distributors in Japan and South Korea

North America



- ❑ Appointment of **Advanced Microscopy Consultancy Services Inc** as North America Distributor

Outlook for 2021

- Commencement of 150 patient Oral Cancer Study at the Melbourne Dental School and Stage 3 of breast cancer trial at Royal Melbourne Hospital
- FDA 510(k) Oral imaging submission planned for first half of CY2021
- Develop distribution strategy for InVivage® into United States market
- Plan regulatory submissions for InVivage® into European and other markets
- Plan clinical studies in additional markets and cancer applications
- Develop machine based learning interpretation of images functionality

Darren Lurie
CEO and Executive Chair
Optiscan Imaging Limited
(ASX:OIL)

www.optiscan.com